Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Swiss 3Rs Day 2025

The Swiss 3Rs Day 2025 is exclusively dedicated to the pivotal theme of 3Rs in Neuroscience. This event is specifically designed to convene researchers, educators, [...]

Go to Top